panitumumab
amgen,takeda
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'improve ']
dr. avallone w/ the improve study: intermittent vs continuous folfiri/pani for 1l ras/braf wt mcrc. 83-85% l sided tumors. pfsot (on treatment) was 12.6 vs 17.6 months with 1 year pfsot of 51.7 vs 61.3%. looks like l sided benefits, r does not. #asco22 
Gastrointestinal medical oncology, cancer of unknown primary, and value-based cancer care delivery. Tweets mine.